Jay Venkatesan, Angion CEO
July 26, 2022 07:20 AM EDT
R&D

Fol­low­ing a host of tri­al flops, An­gion halts R&D work, search­es for ‘strate­gic al­ter­na­tives’

Lei Lei Wu

News Reporter

Af­ter scrap­ping a Phase II kid­ney dis­ease study last month, it ap­pears An­gion Bio­med­ica may be out of moves.

The Union­dale, NY-based biotech an­nounced Mon­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Is there room for MASH drugs in a GLP-1 world?

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times